NASDAQ:INTS Intensity Therapeutics Q2 2026 Earnings Report $4.25 +0.05 (+1.19%) Closing price 08/6/2026 04:00 PM EasternExtended Trading$4.28 +0.03 (+0.59%) As of 08/6/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Intensity Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.87Beat/MissN/AOne Year Ago EPSN/AIntensity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIntensity Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Intensity Therapeutics Earnings HeadlinesIntensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026August 4 at 8:00 AM | prnewswire.comIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)July 15, 2026 | prnewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 7 at 1:00 AM | Investors Alley (Ad)Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6July 1, 2026 | prnewswire.comIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical AwardMay 14, 2026 | prnewswire.comIntensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comSee More Intensity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email. Email Address About Intensity TherapeuticsIntensity Therapeutics (NASDAQ:INTS), Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.View Intensity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is FallingWestern Digital Stock Falls 12% Despite Beating Earnings EstimatesBed Bath & Beyond Renovates: The Neighborhood BlueprintOne Comment on CVS's Earnings Call Sent the Stock TumblingSpaceX: Love the Company, But the Stock Is a Harder CallDisney Sets Up for a Magical Year in 2027 Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
